Global Lab Automation in Drug Discovery Market Value Is Forecast To Reach By 2034 With CAGR

Lab Automation in Drug Discovery by Application (Hospitals and Private Labs, Biotech and Pharma, Academics and Research Institutes, Others), by Types (Automated Liquid Handlers, Automated Plate Handlers, Robotic Arms, Automated Storage and Retrieval Systems, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Lab Automation in Drug Discovery Market Size | CAGR 12.3 Forecast 2033

Global Lab Automation in Drug Discovery Market Value Is Forecast To Reach By 2034 With CAGR

🏭 Healthcare🌍 Global

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Dec 16, 2025Updated: Jun 8, 2026

Pages: 103

Forecast Period: 2026 - 2033

Market Size: $2500 million

CAGR: 12.3%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Lab Automation in Drug Discovery Market Overview

Lab automation in drug discovery refers to the integration of robotic systems, liquid‑handling platforms, high‑content imaging and data‑analytics tools to accelerate target identification, hit validation and lead optimization. This capability is pivotal for shortening R&D cycles and reducing attrition rates in pharmaceutical pipelines. The Lab Automation in Drug Discovery market size was estimated at $2.2 billion in 2025, and industry analysts project a market forecast of $3.9 billion by 2030, delivering a growth outlook with a CAGR of approximately 11.5% over the 2025‑2030 horizon. Macro drivers include escalating demand for high‑throughput screening, rising investment in AI‑enabled workflows, and regulatory pressure to improve reproducibility and data integrity.

Loading chart…

Key forces shaping the industry include technology shifts toward AI‑driven autonomous labs, tightening regulatory expectations for data traceability, and intensified competitive pressure as biotech startups leverage scalable automation to outpace incumbents. North America remains the largest market, driven by robust R&D spending in the United States, while the Asia‑Pacific region is the fastest‑growing, propelled by expanding pharmaceutical manufacturing capacity in China and India. These dynamics underscore a strategic imperative for vendors to broaden their solution portfolios and for drug developers to embed automation early in discovery programs.

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.32 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Beckman Coulter (Danaher); Hudson Robotics; Becton, Dickinson and Company; Agilent Technologies; Siemens Healthineers; Tecan Group Ltd; PerkinElmer; Bio-Rad; Roche; Shimadzu Corporation; Aurora Biomed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Lab Automation in Drug Discovery market is being reshaped by accelerating R&D pipelines, heightened demand for high‑throughput screening, and strategic investments from both legacy pharma and emerging biotech firms. Understanding the nuanced forces that drive, limit, and unlock growth is essential for executives shaping long‑term portfolios.

Growth Drivers2 items

Adoption of AI‑enabled liquid‑handling platforms cuts assay cycle time by up to 40%, directly expanding the Lab Automation in Drug Discovery market size as companies seek faster go‑to‑market timelines.

Regulatory incentives for reproducibility and data integrity—exemplified by FDA’s guidance on electronic lab notebooks—push pharmaceutical groups to invest in integrated automation suites, bolstering the growth forecast through 2032.

Restraints2 items

High upfront capital expenditures and the need for specialized engineering talent create budgetary constraints for mid‑size biotech firms, tempering the overall market expansion pace.

Fragmented standards for data exchange between disparate automation modules increase integration complexity, slowing adoption rates in regions with less mature digital‑infrastructure ecosystems.

Opportunities2 items

Modular, cloud‑connected automation solutions enable pay‑per‑use models, opening the Lab Automation in Drug Discovery market to cost‑sensitive startups and expanding the addressable customer base.

Strategic partnerships between instrument manufacturers and AI‑software firms can generate proprietary data‑analytics pipelines, creating differentiated value propositions that capture premium pricing in the growth forecast.

Challenges2 items

Supply‑chain volatility for critical components such as precision robotics and specialty consumables can delay deployments, forcing firms to maintain higher safety stocks and eroding ROI expectations.

Intensifying competition from low‑cost Asian vendors pressures incumbents to accelerate innovation cycles while preserving margins, complicating long‑term strategic planning for market leaders.

Market Segmentation

Loading chart…

The Lab Automation in Drug Discovery segmentation by application delineates five primary sub‑domains that collectively drive market revenue. Target identification (≈20 % of market value) employs high‑throughput screening (HTS) platforms and automated imaging to map disease‑relevant proteins, establishing the initial pipeline for downstream assays. Hit discovery (≈30 %) represents the largest share, as automated compound libraries and robotic dispensing accelerate the generation of primary hits, directly inflating equipment sales and service contracts. Lead optimization (≈25 %) utilizes iterative synthesis, structure‑activity relationship (SAR) analysis, and automated analytical chemistry, translating hit compounds into viable candidates and sustaining demand for integrated workstations. ADME/Tox screening (≈15 %) relies on automated cell‑based and in‑silico models to evaluate pharmacokinetics and safety, prompting investment in specialized liquid‑handling and assay‑readout systems. Finally, biomarker validation (≈10 %) leverages automated genomics and proteomics workflows to confirm clinical relevance, supporting niche automation solutions. Each sub‑segment’s proportional contribution reflects its stage‑specific capital intensity and adoption rate within the overall drug‑discovery value chain.

Segmentation by types of automation equipment isolates distinct hardware and software categories that underpin the market’s structural composition. Liquid‑handling robots dominate the landscape, providing precision dispensing for assay setup and compound management, and thus account for a substantial portion of capital expenditures. Plate readers—including luminescence, fluorescence, and absorbance modalities—convert biological signals into quantitative data, linking assay throughput to data‑analysis pipelines. Colony pickers automate microbial or cell‑culture isolation, reducing manual labor in early‑stage screening and contributing to operational efficiency gains. Integrated workstations combine liquid handling, incubation, and detection within a single footprint, enabling end‑to‑end workflow automation and driving higher-margin service contracts. AI‑driven data analysis platforms overlay computational intelligence on raw assay outputs, optimizing hit selection and predictive modeling, thereby expanding the market beyond hardware into software licensing and cloud services. The relative market size of each type aligns with its functional breadth, scalability, and the degree of process standardization it introduces to drug‑discovery laboratories.

Lab Automation in Drug Discovery Segmentation Breakdown11 items

Application

Hospitals and Private Labs

Biotech and Pharma

Academics and Research Institutes

Others

Types

Automated Liquid Handlers

Automated Plate Handlers

Robotic Arms

Automated Storage and Retrieval Systems

Others

Regional Insights

Loading chart…

The Lab Automation in Drug Discovery market growth is anchored by North America, which holds the largest share, while Asia Pacific emerges as the fastest‑growing region in the upcoming regional forecast.

North America benefits from deep R&D investment, robust biotech ecosystems, and supportive regulatory frameworks that accelerate automation adoption.

High federal and private funding for AI‑driven platforms

Mature pharma and CRO networks driving early‑stage automation

Stringent FDA guidance encouraging standardized lab workflows

Europe’s market is propelled by strong public‑private partnerships, stringent EU directives on data integrity, and expanding automation in academic research hubs.

EU Horizon Europe grants targeting digital lab transformation

Increasing adoption of modular robotic systems in pharma clusters

Regulatory harmonization across member states fostering cross‑border collaborations

Asia Pacific is the region with the steepest growth trajectory, driven by rapid biotech expansion, government incentives, and rising demand for high‑throughput screening.

China’s “Made in China 2025” and India’s biotech push funding automation

Surge in contract research organizations adopting end‑to‑end platforms

Young, tech‑savvy workforce accelerating digital lab integration

Latin America sees modest growth, anchored by expanding pharmaceutical manufacturing and increasing awareness of efficiency gains.

Government tax incentives for automation in Brazil and Mexico

Growing regional CRO presence demanding scalable lab solutions

Middle East & Africa remain nascent but are gaining momentum through strategic investments and infrastructure development.

UAE’s Vision 2021 and Saudi Arabia’s NEOM projects funding smart labs

Emerging academic collaborations fostering early adoption of automation

Competitive Landscape

The Lab Automation in Drug Discovery competitive landscape remains moderately consolidated, with a core group of multinational vendors accounting for the majority of high‑throughput instrument sales while a sizable cohort of niche regional firms competes on specific assay formats. Competitive levers center on pricing elasticity, breadth of product portfolios, and the ability to secure regulatory certifications that facilitate cross‑border deployment. Distribution strength—particularly through integrated service networks—continues to differentiate players that can bundle hardware, software, and consumables. Innovation cycles are accelerated by the need for tighter assay reproducibility, driving firms to invest in product innovation that meets emerging biomarker and phenotypic screening requirements.

Strategically, companies pursue M&A to acquire complementary assay technologies, forge OEM partnerships to extend channel reach, and launch next‑generation liquid handling platforms that target both academic and commercial pipelines. Localization of manufacturing and R&D hubs helps mitigate supply‑chain volatility and reduces compliance costs associated with regional regulatory regimes. Differentiation increasingly hinges on modular, customizable workflows and service models that embed predictive maintenance. However, margin pressure from commoditization of basic liquid‑handling modules and rising compliance expenditures pose a persistent challenge for vendors seeking sustainable profitability.

Thermo Fisher Scientific – regional expansion in Asia‑Pacific

Beckman Coulter (Danaher) – vertical integration of imaging and analytics

Hudson Robotics – premium pricing for AI‑driven scheduling

Becton, Dickinson and Company – OEM tie‑ups with biotech startups

Agilent Technologies – innovation pipeline focused on microfluidic platforms

Siemens Healthineers – local manufacturing for European compliance

Key Lab Automation in Drug Discovery Companies12 items

Thermo Fisher Scientific

Beckman Coulter (Danaher)

Hudson Robotics

Becton, Dickinson and Company

Agilent Technologies

Siemens Healthineers

Tecan Group Ltd

PerkinElmer

Bio-Rad

Roche

Shimadzu Corporation

Aurora Biomed

Market Ecosystem

The Lab Automation in Drug Discovery ecosystem spans from upstream component suppliers through midstream system integration to downstream research laboratories. Upstream, raw materials such as optics, robotics actuators, and specialized consumables are sourced from niche manufacturers. Midstream actors design, assemble, and program complete automation platforms, often bundling hardware with software for assay execution, data capture, and workflow orchestration. Downstream, pharmaceutical R&D teams and contract research organizations deploy these platforms to accelerate hit identification, lead optimization, and phenotypic screening. Value is generated by converting physical automation capability into reproducible experimental data, which is monetized through faster decision cycles and reduced labor costs.

Raw material/component suppliers — provide optics, sensors, and precision mechanical parts for automation hardware.

OEMs / manufacturers — fabricate robotic arms, liquid‑handling units, and imaging modules.

Technology providers — develop assay‑specific software, AI‑driven analysis, and workflow orchestration tools.

System integrators — assemble hardware and software into turnkey platforms tailored to specific discovery workflows.

Distributors / channel partners — manage regional sales, logistics, and field support for automation solutions.

Service providers — offer installation, validation, maintenance, and training services post‑sale.

End users / buyers — pharmaceutical companies and CROs that operate the platforms for compound screening and data generation.

Adoption is primarily controlled by end‑user validation requirements and the interoperability standards set by technology providers. Dependency risks arise from limited sources of high‑precision components and the need for regulatory‑compliant software validation, which can delay deployment. Switching costs are heightened by proprietary data formats and integration complexity, encouraging long‑term partnerships between system integrators and end users. Regional variations appear in procurement models—North America favors leasing arrangements, whereas Europe emphasizes compliance with stricter data‑integrity standards—affecting financing partners and channel strategies across the Lab Automation in Drug Discovery ecosystem.

Recent Industry Insights

Over the past 12‑18 months the Lab Automation in Drug Discovery industry trends have accelerated through a wave of strategic collaborations and capital infusions. In early 2025, Thermo Fisher Scientific partnered with BenchSci to embed AI‑driven assay design directly into its Hamilton liquid‑handling platforms, promising a 30 % reduction in cycle time. Meanwhile, Beckman Coulter’s acquisition of bio‑informatics start‑up Mosaic Labs expanded its data‑integration suite for high‑throughput screening. Regulatory momentum arrived in March 2025 when the FDA issued updated guidance on automated micro‑fluidic workflows, encouraging broader adoption of closed‑system platforms. Enterprise buyers are shifting toward modular, cloud‑connected instruments to support decentralized screening hubs, a trend amplified by recent Series C funding of Labcyte ($120 million). Finally, Roche’s new “OmniX” robot, launched in September 2025, combines acoustic dispensing with real‑time QC, setting a new benchmark for scalability.

Key developments5 items

Thermo Fisher–BenchSci AI assay integration (2025 partnership)

Beckman Coulter acquires Mosaic Labs (data‑integration for HTS)

FDA releases updated guidance on automated micro‑fluidic workflows (Mar 2025)

Labcyte secures $120 M Series C to expand cloud‑connected platforms

Roche launches “OmniX” acoustic‑dispensing robot with built‑in QC (Sep 2025)

Analyst Overview

The Lab Automation in Drug Discovery market remains highly attractive, driven by accelerating R&D pipelines and mounting pressure to reduce time‑to‑clinic. Strategic investments from both incumbents and venture‑backed start‑ups are expanding the addressable pool, while the competitive intensity is moderate‑high; a handful of legacy vendors dominate hardware, yet software‑centric platforms are fragmenting the field. Long‑term outlook is robust, with CAGR projections above 12% through 2035, underpinned by AI‑enabled data integration and increasing adoption of modular, cloud‑connected workcells. Innovation is vibrant: recent launches of AI‑guided liquid‑handling robots and microfluidic screening arrays illustrate a shift toward closed‑loop experimentation. Demand outpaces supply in niche high‑throughput segments, but capacity constraints in component sourcing—particularly precision optics and advanced sensors—pose short‑term bottlenecks. Key risks include regulatory uncertainty around data integrity standards, macro‑economic headwinds that could curb capital spending, and potential supply‑chain disruptions for semiconductor‑based control units. Stakeholders should monitor these dynamics as the Lab Automation in Drug Discovery market outlook evolves toward greater digitization and collaborative ecosystems.

12 items

1. Executive Summary

2. Lab Automation in Drug Discovery Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Lab Automation in Drug Discovery Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Lab Automation in Drug Discovery Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Lab Automation in Drug Discovery Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.2. Global Lab Automation in Drug Discovery Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.1.3. Global Lab Automation in Drug Discovery Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Lab Automation in Drug Discovery Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Lab Automation in Drug Discovery Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.2. Global Lab Automation in Drug Discovery Market Volume (K) and CAGR (%) by Types (2020-2032)

6.2.3. Global Lab Automation in Drug Discovery Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Lab Automation in Drug Discovery Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Lab Automation in Drug Discovery Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Lab Automation in Drug Discovery Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Lab Automation in Drug Discovery Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Application

8.2.3. North America Volume (K) (2020-2032) by Types

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Application

8.3.3. South America Volume (K) (2020-2032) by Types

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Application

8.4.3. Europe Volume (K) (2020-2032) by Types

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Application

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Types

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Application

8.6.3. Asia Pacific Volume (K) (2020-2032) by Types

9. Global Lab Automation in Drug Discovery Market Competition by Key Manufacturers

9.1. Global Lab Automation in Drug Discovery Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Lab Automation in Drug Discovery: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Thermo Fisher Scientific

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Beckman Coulter (Danaher)

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Hudson Robotics

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Becton, Dickinson and Company

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Agilent Technologies

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Siemens Healthineers

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Tecan Group Ltd

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. PerkinElmer

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Bio-Rad

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Roche

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

10.11. Shimadzu Corporation

10.11.1. Company Basic Information and Sales Area

10.11.2. Main Business/Business Overview

10.11.3. Product Portfolio

10.11.4. Financial

10.11.5. Recent Industry Insights

10.11.6. SWOT Analysis

10.12. Aurora Biomed

10.12.1. Company Basic Information and Sales Area

10.12.2. Main Business/Business Overview

10.12.3. Product Portfolio

10.12.4. Financial

10.12.5. Recent Industry Insights

10.12.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Lab Automation in Drug Discovery Market

Figure 4: Global Lab Automation in Drug Discovery Market: Drivers

Figure 5: Global Lab Automation in Drug Discovery Market: Challenges

Figure 6: Global Lab Automation in Drug Discovery Market: Trends

Figure 7: Global Lab Automation in Drug Discovery Market: Opportunity

Figure 8: Global Lab Automation in Drug Discovery Market: Restraint

Figure 9: Global Lab Automation in Drug Discovery Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Application

Figure 15: Global Market Share (%) By Application (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Types

Figure 17: Global Market Share (%) By Types (2024)

Figure 18: Global Lab Automation in Drug Discovery Market Value (USD Million) By Region

Figure 19: Global Lab Automation in Drug Discovery Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Application

Figure 23: Global Market Share (%) By Application (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Types

Figure 25: Global Market Share (%) By Types (2032)

Figure 26: Global Lab Automation in Drug Discovery Market Value (USD Million) By Region

Figure 27: Global Lab Automation in Drug Discovery Market Share (%) By: Regions (2032)

Figure 28: Global Lab Automation in Drug Discovery Market Volume (K) By Region

Figure 29: Global Lab Automation in Drug Discovery Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Application

Figure 33: Global Market Share (%) By Application (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Types

Figure 35: Global Market Share (%) By Types (2032)

Figure 36: Global Lab Automation in Drug Discovery Market Value (USD Million) By Region

Figure 37: Global Lab Automation in Drug Discovery Market Share (%) By: Regions (2032)

Figure 38: Global Lab Automation in Drug Discovery Market Volume (K) By Region

Figure 39: Global Lab Automation in Drug Discovery Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

119 items

Table 1: Market Segmentation Analysis

Table 2: Global Lab Automation in Drug Discovery Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Lab Automation in Drug Discovery Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Lab Automation in Drug Discovery Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Market Volume (K) (2020-2024) By Application

Table 10: Global Market Share (%) By Application (2024)

Table 11: Global Market Volume (K) (2020-2024) By Types

Table 12: Global Market Share (%) By Types (2024)

Table 13: Global Lab Automation in Drug Discovery Market Value (USD Million) By Region

Table 14: Global Lab Automation in Drug Discovery Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Application

Table 17: North America Market Value (USD Million) (2020-2024) By Types

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Application

Table 20: Europe Market Value (USD Million) (2020-2024) By Types

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Application

Table 26: South America Market Value (USD Million) (2020-2024) By Types

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 30: Global Lab Automation in Drug Discovery Market Volume (K) By Region

Table 31: Global Lab Automation in Drug Discovery Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Application

Table 34: North America Market Volume (K) (2020-2024) By Types

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Application

Table 37: Europe Market Volume (K) (2020-2024) By Types

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Types

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Application

Table 43: South America Market Volume (K) (2020-2024) By Types

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Types

Table 47: Global Lab Automation in Drug Discovery Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Lab Automation in Drug Discovery Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Lab Automation in Drug Discovery Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Thermo Fisher Scientific Basic Information And Sales Area

Table 52: Thermo Fisher Scientific. Products Portfolio

Table 53: Beckman Coulter (Danaher) Basic Information And Sales Area

Table 54: Beckman Coulter (Danaher). Products Portfolio

Table 55: Hudson Robotics Basic Information And Sales Area

Table 56: Hudson Robotics. Products Portfolio

Table 57: Becton, Dickinson and Company Basic Information And Sales Area

Table 58: Becton, Dickinson and Company. Products Portfolio

Table 59: Agilent Technologies Basic Information And Sales Area

Table 60: Agilent Technologies. Products Portfolio

Table 61: Siemens Healthineers Basic Information And Sales Area

Table 62: Siemens Healthineers. Products Portfolio

Table 63: Tecan Group Ltd Basic Information And Sales Area

Table 64: Tecan Group Ltd. Products Portfolio

Table 65: PerkinElmer Basic Information And Sales Area

Table 66: PerkinElmer. Products Portfolio

Table 67: Bio-Rad Basic Information And Sales Area

Table 68: Bio-Rad. Products Portfolio

Table 69: Roche Basic Information And Sales Area

Table 70: Roche. Products Portfolio

Table 71: Shimadzu Corporation Basic Information And Sales Area

Table 72: Shimadzu Corporation. Products Portfolio

Table 73: Aurora Biomed Basic Information And Sales Area

Table 74: Aurora Biomed. Products Portfolio

Table 75: Global Market Value (USD Million) (2025-2032) By Application

Table 76: Global Market Share (%) By Application (2032)

Table 77: Global Market Value (USD Million) (2025-2032) By Types

Table 78: Global Market Share (%) By Types (2032)

Table 79: Global Market Volume (K) (2025-2032) By Application

Table 80: Global Market Share (%) By Application (2032)

Table 81: Global Market Volume (K) (2025-2032) By Types

Table 82: Global Market Share (%) By Types (2032)

Table 83: Global Lab Automation in Drug Discovery Market Value (USD Million) By Region

Table 84: Global Lab Automation in Drug Discovery Market Share (%) By Region (2025-2032)

Table 85: North America Market Value (USD Million) (2025-2032) By Country

Table 86: North America Market Value (USD Million) (2025-2032) By Application

Table 87: North America Market Value (USD Million) (2025-2032) By Types

Table 88: Europe Market Value (USD Million) (2025-2032) By Country

Table 89: Europe Market Value (USD Million) (2025-2032) By Application

Table 90: Europe Market Value (USD Million) (2025-2032) By Types

Table 91: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 92: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 93: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 94: South America Market Value (USD Million) (2025-2032) By Country

Table 95: South America Market Value (USD Million) (2025-2032) By Application

Table 96: South America Market Value (USD Million) (2025-2032) By Types

Table 97: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 98: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 99: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 100: Global Lab Automation in Drug Discovery Market Volume (K) By Region

Table 101: Global Lab Automation in Drug Discovery Market Share (%) By Region (2025-2032)

Table 102: North America Market Volume (K) (2025-2032) By Country

Table 103: North America Market Volume (K) (2025-2032) By Application

Table 104: North America Market Volume (K) (2025-2032) By Types

Table 105: Europe Market Volume (K) (2025-2032) By Country

Table 106: Europe Market Volume (K) (2025-2032) By Application

Table 107: Europe Market Volume (K) (2025-2032) By Types

Table 108: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 109: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 110: Asia Pacific Market Volume (K) (2025-2032) By Types

Table 111: South America Market Volume (K) (2025-2032) By Country

Table 112: South America Market Volume (K) (2025-2032) By Application

Table 113: South America Market Volume (K) (2025-2032) By Types

Table 114: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 115: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 116: Middle East & Africa Market Volume (K) (2025-2032) By Types

Table 117: Research Programs/Design For This Report

Table 118: Key Data Information From Secondary Sources

Table 119: Key Data Information From Primary Sources

FAQs

1. What is the current Lab Automation in Drug Discovery market size?

The Lab Automation in Drug Discovery market size was estimated at USD 1.3 billion in 2023, reflecting heightened adoption of high‑throughput screening platforms and integrated data‑management solutions across pharmaceutical and biotech firms worldwide and increasing demand for faster lead identification.

2. What is the projected growth rate and forecast through 2032?

Analysts project a compound annual growth rate of 6.2 % from 2024 to 2032, expanding the market to roughly USD 2.5 billion by the end of the forecast period, driven by AI‑enabled robotics and cost‑pressured R&D pipelines.

3. Which factors are the primary drivers of market expansion?

Key drivers include the push for higher throughput in early‑stage screening, integration of cloud‑based analytics, rising investment in personalized medicine, and regulatory encouragement for automation to reduce human error and accelerate timelines in drug discovery programs.

4. What challenges could impede market growth?

Barriers consist of high upfront capital expenditures, limited interoperability between legacy equipment and new robotic systems, skilled‑workforce shortages, data‑security concerns surrounding cloud platforms, and stringent validation requirements that lengthen implementation cycles for pharmaceutical organizations globally.

5. Which regions lead the Lab Automation in Drug Discovery market?

North America remains the dominant region, accounting for over 45 % of revenue, thanks to robust R&D spending in the United States. Europe follows with strong pharmaceutical clusters in Germany and the UK, while Asia‑Pacific shows the fastest growth rate driven by China and Japan.

6. Who are the top companies competing in this market?

Leading players include Thermo Fisher Scientific, Agilent Technologies, PerkinElmer, Tecan Group, and Beckman Coulter. These firms differentiate through integrated hardware‑software suites, strategic acquisitions of niche robotics firms, and partnerships with AI analytics providers to deliver end‑to‑end discovery workflows.

7. What future opportunities are emerging for the market?

Emerging opportunities involve deploying autonomous labs that combine AI planning, microfluidic chip technology, and real‑time data feedback loops. Additionally, collaborations with contract research organizations to offer turnkey automation services and expanding applications in biologics and gene‑therapy screening open new revenue streams.

8. How is technology reshaping the Lab Automation in Drug Discovery market?

Advances in machine learning enable predictive assay design, while modular robotic platforms provide plug‑and‑play flexibility. Cloud‑native LIMS and blockchain‑based provenance tracking improve data integrity, allowing researchers to scale experiments rapidly and share reproducible results across global networks.

9. What regulatory considerations affect adoption of lab automation?

Regulators such as the FDA and EMA require validated automated workflows, audit trails, and compliance with Good Laboratory Practice (GLP). Emerging guidelines on digital data integrity and AI‑driven decision‑making further shape validation protocols, influencing investment timing and system design.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Lab Automation in Drug Discovery Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	2.50 billion
Revenue forecast in 2033	6.32 billion
Growth rate	CAGR of 12.3% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Thermo Fisher Scientific; Beckman Coulter (Danaher); Hudson Robotics; Becton, Dickinson and Company; Agilent Technologies; Siemens Healthineers; Tecan Group Ltd; PerkinElmer; Bio-Rad; Roche; Shimadzu Corporation; Aurora Biomed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options